Nirvana Life Sciences Inc.
NIRVX
CNSX
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.14% | -11.67% | -31.33% | -44.18% | -60.81% |
| Depreciation & Amortization | -291.11% | -163.70% | -163.70% | -163.70% | -82.63% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.92% | -26.92% | -44.07% | -56.21% | -63.25% |
| Operating Income | 8.92% | 26.92% | 44.07% | 56.21% | 63.25% |
| Income Before Tax | 36.99% | 48.40% | 58.73% | 68.49% | 63.55% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 36.99% | 48.40% | 58.73% | 68.49% | 63.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -175.00% | -120.00% | -111.76% | -113.64% | -88.57% |
| Net Income | 36.89% | 48.20% | 58.58% | 68.37% | 63.47% |
| EBIT | 8.92% | 26.92% | 44.07% | 56.21% | 63.25% |
| EBITDA | 56.16% | 53.90% | 51.31% | 55.17% | 62.40% |
| EPS Basic | 57.08% | 71.75% | 78.63% | 81.11% | 74.44% |
| Normalized Basic EPS | 29.45% | 61.38% | 72.45% | 78.46% | 80.77% |
| EPS Diluted | 57.08% | 71.75% | 78.63% | 81.11% | 74.44% |
| Normalized Diluted EPS | 29.45% | 61.38% | 72.45% | 78.46% | 80.77% |
| Average Basic Shares Outstanding | -30.43% | 59.13% | 564.28% | 487.44% | 511.51% |
| Average Diluted Shares Outstanding | -30.43% | 59.13% | 564.28% | 487.44% | 511.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |